Lantheus (LNTH) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lantheus (LNTH) has outperformed Alpha Teknova (TKNO) over the past year, gaining 82.9% versus a gain of 77.4%. Over five years, LNTH leads with a +266.1% price change compared with -63.6% for TKNO. Lantheus is the larger company by market cap ($6.68 billion vs $480.0 million), about 13.9 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs +0.5%).
Lantheus converts more of its revenue into profit, with a net margin of 15.2% versus -42.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | TKNO |
|---|---|---|
| Share price | $102.10 | $7.63 |
| Market cap | $6.68B | $479.95M |
| 1-day change | 0.00% | -2.30% |
| YTD return | +53.42% | +100.79% |
| 1-year return | +82.91% | +77.44% |
| 5-year return | +266.08% | -63.63% |
| P/E ratio (TTM) | 25.40 | — |
| Forward P/E | 15.34 | — |
| EPS (TTM) | $4.02 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | $40.52M |
| Revenue growth (YoY) | +0.50% | +7.35% |
| Net income (latest FY) | $233.56M | $-17.26M |
| Gross margin | 61.10% | 33.17% |
| Operating margin | 20.16% | -41.90% |
| Net margin | 15.15% | -42.59% |
| 52-week high | $111.86 | $9.48 |
| 52-week low | $54.94 | $1.91 |
| Distance from 52-week high | -8.73% | -19.51% |
| Analyst consensus | hold | none |
| Avg. price target upside | +3.81% | +28.83% |
| Average volume | 1.02M | 437.31K |
| Shares outstanding | 65.40M | 62.90M |
| Employees | 1,193 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 13.9 times larger than Alpha Teknova by market value ($6.68B vs $479.95M).
- Lantheus is more profitable, keeping 15.2 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.
- Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs +0.50%).
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
LNTH vs TKNO FAQ
Which is bigger, Lantheus or Alpha Teknova?
Lantheus (LNTH) is larger, with a market capitalization of $6.68B compared with $479.95M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, LNTH or TKNO?
LNTH returned +82.91% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.